cxcr2-transduced autologous tumor-infiltrating lymphocytes

CXCR2-transduced autologous tumor-infiltrating lymphocytes (TILs) is an investigational adoptive cell therapy developed by MD Anderson Cancer Center for the treatment of metastatic melanoma. The therapy involves harvesting TILs from a patient's tumor, followed by genetic modification using a retroviral vector to express the chemokine receptor CXCR2 and a truncated nerve growth factor receptor (NGFR) as a selection marker. The rationale for this modification is that melanoma cells frequently secrete chemokines such as CXCL1 and CXCL8, but endogenous TILs often lack the corresponding receptor, CXCR2. By engineering TILs to express CXCR2, the therapy aims to enhance the trafficking and infiltration of these T cells into the tumor microenvironment. Following ex vivo expansion, the modified TILs are reinfused into the patient after a lymphodepleting chemotherapy regimen, typically in combination with high-dose interleukin-2 (IL-2) to promote T-cell survival and expansion in vivo.

Other names

CXCR2-transduced TILsCXCR-2-transduced TILsCXCR 2-transduced TILsCXCR2 and NGFR transduced autologous tumor-infiltrating lymphocytesCXCR-2 and NGFR transduced autologous tumor-infiltrating lymphocytesCXCR 2 and NGFR transduced autologous tumor-infiltrating lymphocytesCXCR2-transduced Autologous Tumor Infiltrating LymphocytesCXCR-2-transduced Autologous Tumor Infiltrating LymphocytesCXCR 2-transduced Autologous Tumor Infiltrating Lymphocytes